MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, will present at the Oppenheimer Movers in Rare Disease Summit in New York City on December 12, 2024. Dr. Musunuri’s session will cover the company’s innovative approaches to treating inherited retinal diseases.
“I have witnessed firsthand the impact that Ocugen’s modifier gene therapies have made in the lives of patients with retinitis pigmentosa (RP) and Stargardt disease,” said Dr. Musunuri. “In the coming months, I cannot wait to share more data about these two exciting programs—the Phase 3 OCU400 liMeliGhT clinical trial for RP and Phase 1/2 OCU410ST GARDian clinical trial for Stargardt disease.”
Dr. Musunuri will participate in the “Elevator Pitches from Rare Disease Companies” session, scheduled from 2:45 to 3:30 p.m. ET in Grand Central Ballroom C&D at the Westin Grand Central in New York.
Alongside the presentation, Ocugen’s executive team will host one-on-one meetings with investors to discuss the company’s business strategy and the progress of its clinical development programs.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.